Edwards Resilia Approved for Mitral Valve Replacement

[Croooser]

IRVINE, Calif., March 31, 2022 /PRNewswire/ -- Edwards Lifesciences (NYSE: EW) today announced it received approval from the U.S. Food and Drug Administration (FDA) for the MITRIS RESILIA valve, a tissue valve replacement specifically designed for the heart's mitral position.

https://www.prnewswire.com/news-rel...r-mitral-replacement-surgeries-301514462.html